Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

ering-Plough Pharmaceuticals, reached a civil settlement with a multistate group of attorneys general representing 35 states and the District of Columbia who investigated whether the companies violated state consumer protection laws in connection with the ENHANCE clinical trial or by their promotion and marketing of VYTORIN and ZETIA. (Announced July 15)

Second Quarter 2009 Conference Call and Webcast

Schering-Plough will conduct a conference call today at 7:45 a.m. (EDT) to review the 2009 second quarter results. To listen live to the call, dial 1-866-871-2144 or 1-706-634-5003 and enter conference ID # 13268740. A replay of the call will be available beginning later on July 21 through 5 p.m. on Tuesday, July 28. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID # 13268740. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on July 21 through 5 p.m. on Aug. 21.

DISCLOSURE NOTICE:

The information in this press release, the comments of Schering-Plough officers during the earnings teleconference/webcast on July 21, 2009, beginning at 7:45 a.m. (EDT), and other written reports and oral statements made from time to time by the company may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and are based on current expectations or forecasts of future events. You can identify these forward-looking statements by their use of words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "project," "intend," "plan," "potential," "will," and
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...ies, Inc. today,announced that it has entered into...speed chemistry technologies and capabilities to Z...based biopharmaceutical company which,develops obe...ipose tissue., Under the agreement, Anthill will ...d purification capabilities to assist Zafgen in th...
...inical Picture, Improves,Patient-Physician Communi...a A patients who,use Helixate(R) FS, Antihemophili...ers are now tracking treatment progress in real ti...-art wireless Internet-based,data management syste...llows for a comprehensive view of a patient,s prog...
...ternational Corporation (Nasdaq: PRXL ), a leadin...reveal that U.S. marketing,applications for new mo...,While NME approvals reached a many-year low of 16...) launches declined 19 percent to 25, during 2007,... 2007, up from 21 filed,in 2006, according to PARE...
Other Biology Technology:CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 2CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 3CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 4PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 2PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 3PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 4
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/2/2009)PHILADELPHIA Children exposed to secondhand cigarette smoke have an increased risk of developing lung cancer in adulthood, even if they never smoked. , Results of this study are published in Cance
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Cornflakes White Bread Could Boost Heart Risk 48653 1Cornflakes White Bread Could Boost Heart Risk 48653 2Cornflakes White Bread Could Boost Heart Risk 48653 3Pennsylvania Patient Safety Authority Hires Patient Safety Liaison 28PSL 29 to Help Healthcare Facilities Implement Guidance 48651 1Pennsylvania Patient Safety Authority Hires Patient Safety Liaison 28PSL 29 to Help Healthcare Facilities Implement Guidance 48651 2Pennsylvania Patient Safety Authority Hires Patient Safety Liaison 28PSL 29 to Help Healthcare Facilities Implement Guidance 48651 3Study shows promise for new cancer stopping therapy 48649 1Study shows promise for new cancer stopping therapy 48649 2
...mans is often associated with decline and a loss o...alled senescence -- is proving to be one of ironic...tory (CSHL) today reported that a particular class...of events in living mice that can limit fibrosis, ... The surprising finding follows on the heels of e...
... . , Bremerhaven, August 19th 2008. German rese...ener Institute for Polar and Marine Research in th...ssage for the first time. Polarstern left the port...and on a southern course and is located right in t...Siberian Sea where geoscientific measurements at t...
...awaii, the Wildlife Conservation Society, Smithso...Fisheries Service and Projecto Meros do Brazil dis...s more than six feet in length and can weigh nearl...be found roaming the tropical reefs of the Eastern...ong the corals and sea grass to evade marine biolo...
Other Biology News:Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage 2Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage 3Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage 4RV Polarstern on its way to East Siberian Sea 2RV Polarstern on its way to East Siberian Sea 3Genetics reveals big fish that almost got away 2
...bulizers are available in two product models - the... two models is that the 6000AT+ includes a membran... aerosol for improved detection limits and reduced...on limits for a range of elements by 10-40 times. ...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related ...ailability of new radiolabeled ligands selected to...s a wide range of products and services for recept... state-of-the-art radioligands. If you do not find...
AMV RT HC 600 U from Invitrogen
...ding) was developed using a protein engineering ap... DNA binding pocket of wild-type DNase I. These ch...n for DNA. The result is a versatile enzyme that h...intain at least 50% of peak activity in solutions ...
Biology Products: